Clinical Trial Update: ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ZD1839 (gefitinib) with oral irinotecan in young patients with refractory solid tumors, including glioblastoma, rhabdomyosarcoma, neuro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma

Drugs mentioned

• Irinotecan (oral) (irinotecan)
• ZD1839 (Gefitinib) (gefitinib)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Glioblastoma, Rhabdomyosarcomas | Phase 1 | Status: COMPLETED